Mayo Clinic researchers have developed and evaluated MedEduChat, an electronic health record (EHR) that works with a large ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Plans to seek regulatory approval to commence a Phase III trial in the US and CanadaVANCOUVER, BC, Jan. 8, 2026 /PRNewswire/ -- Sustained Therapeutics ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approval at its 2025 Extraordinary General Shareholders' Meeting, that Foresee Pharmaceuticals USA Inc., the Company's ...

Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC.Foresee will receive a 10 million USD upfront payment, potential milestones of ...

Researchers at the University of California San Diego have now developed a groundbreaking “one-click” AI tool that could ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments proved "life changing". While most patients have 20 days of radiotherapy over ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Alongside laboratory research, clinicians continue to stress the importance of awareness. Maintaining a healthy diet, staying physically active, and seeking medical advice for symptoms such as rectal ...